XML 18 R2.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 18,905 $ 4,576
Marketable securities 196,323 52,174
Accounts receivable $ 6 $ 37
Accounts Receivable, after Allowance for Credit Loss, Current, Related Party [Extensible Enumeration] Related Party [Member] Related Party [Member]
Prepaid and other current assets $ 5,731 $ 1,427
Total current assets 220,965 58,214
Property and equipment, net 830 220
Operating lease right-of-use asset 659 839
Investment in Angel Pharmaceuticals 15,107 10,991
Other assets 1,713 855
Total assets 239,274 71,119
Current liabilities:    
Accounts payable 4,047 2,491
Operating lease liability 454 403
Accrued and other liabilities 9,171 6,486
Total current liabilities 13,672 9,380
Operating lease liability 274 534
Total liabilities 13,946 9,914
Commitments and contingencies (Note 15)
Stockholders' equity:    
Preferred stock: $0.0001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; 0 shares issued and outstanding at each of June 30, 2026 and December 31, 2025
Common stock: $0.0001 par value; 290,000,000 shares authorized at June 30, 2026 and December 31, 2025; 84,120,944 and 74,696,629 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively 8 7
Additional paid-in capital 670,557 474,387
Accumulated other comprehensive loss (1,293) (896)
Accumulated deficit (443,944) (412,293)
Total stockholders' equity 225,328 61,205
Total liabilities and stockholders' equity $ 239,274 $ 71,119